The recently revised European LeukemiaNet (ELN-2017) recommendations for diagnosis and management of adult patients with acute myeloid leukemia (AML) are broadly accepted by physicians as a gold standard and provide guidelines to stratify patients into three outcome groups: favorable, intermediate, and adverse based on cytogenetics and mutation status of ASXL1, CEBPA, FLT3, NPM1, RUNX1, and TP53 [1]. This evidence concerns the gene FLT3 and acute myeloid leukemia.